Key Leadership Team:
Passionate About Transforming RNA Therapy

Chimeron Bio is led by seasoned scientific experts with deep pharma and R&D experience, and who are driven to deliver better, safer, and more effective medicines to patients in need.

Jolly Mazumdar, Ph.D., MBA
Chief Executive Officer

Jolly Mazumdar is the Chief Executive Officer of Chimeron Bio. Previously, she served in clinical development leadership roles at GlaxoSmithKline pharmaceuticals in the divisions of Immuno-Oncology and Personalized Oncology where she oversaw the biomarker strategy for two melanoma drugs, Tafinlar and Mekinist. Jolly obtained her Ph.D. in Cell Biology with emphasis in infectious diseases from the University of Georgia. She pursued her postdoctoral training in a Howard Hughes Medical Institute laboratory at the University of Pennsylvania where she explored the role of hypoxia in tumor and stem cell biology. Her research is published in journals including Nature Cell Biology and PNAS. Jolly has an M.B.A. from Columbia Business School.

Thimmaiah (Tim) Chendrimada, Ph.D., MBA
Chief Scientific Officer

Tim Chendrimada brings in 12 years of drug discovery and development experience across therapy areas including cardiovascular and oncology obtained at GlaxoSmithKline (GSK) pharmaceuticals.  He has led multiple pre-clinical programs and has experience with therapeutic entities including small molecules, antibodies, AAVs and RNA oligos.  Previously, at the Wistar Institute in Philadelphia, he worked on understanding RNA biochemistry, with emphasis on biogenesis and maturation of small RNAs.  His research is published in high-profile journals including Nature, Cell, EMBO.  Tim obtained his Ph.D. at the University of Georgia and has an MBA from Columbia Business School.

Afshin Safavi, Ph.D.
Chairman of the Board

Dr. Afshin Safavi is a veteran biochemist with extensive experience establishing and leading bioanalytical teams in pharmaceutical, biotechnology, and manufacturing companies, as well as contract research organizations. He is founder of BioAgilytix and is considered an expert in various immunoassay platforms and biomarker analysis.

Prior to founding BioAgilytix and acting as the Global Chief Scientific Officer, he was the Director of Ligand Binding and Immunoassay at AAIPharma. At Talecris BioTherapeutics he led the Preclinical and Clinical Assay Development team, building on his experience as a senior scientist at Nobex Corporation, GlaxoSmithKline and IGEN International. He obtained his BS in Biochemistry from UCLA, his PhD in Biochemistry from University of Kentucky Medical School and completed a two-year postdoctoral assignment at the Emory University Department of Pathology.

Monica (Monty) Coleman, CPA
Chief Financial Officer

Monica Coleman is a seasoned finance professional with over 30 years of tactical financial expertise in all areas of accounting. She has extensive experience with cash flow optimization, budget creation and administration, contract negotiations, P&L accountability and ERP systems management. She has been instrumental in re-engineering processes resulting in efficiencies seen throughout organizations.

Most recently, she spent 10 years at BioAgilytix Labs, building the finance function from the ground up and played a pivotal role in due diligence through two sales of the Company. Prior to BioAgilytix Labs, she was a Partner with Rankin McKenzie, a leading provider of fractional CFOs and Controllers in the Research Triangle Park, NC area for eight years. At Rankin McKenzie, she provided CFO services encompassing all aspects of finance processes as well as setting up human resource policies to a variety of mostly life science start-up companies.

Monica received her B.S. magna cum laude in Business Administration, Accounting Emphasis from Wingate University and is a licensed Certified Public Accountant in North Carolina.

Dominique Gouty, Ph.D.
Scientific Advisory Board Member

Dr. Dominique Gouty brings over 25 years of business leadership experience in multi-national Pharmaceutical/Healthcare and Services industries, spanning R&D, clinical operations, diagnostics, manufacturing of Biologics and Bioanalytical testing of Protein Drugs, Cell Therapies and Gene Therapies.

Dr. Gouty most recently served as the Chief Scientific Officer at BioAgilytix, a contract research laboratory. Over her tenure she participated in successfully bringing half of all the biologic drugs (including gene and cell therapies) to final approval by the FDA.  Before this she led an international pharma division of a contract research laboratory specializing in small and large molecule services. Her strategic leadership role led to the building of several market-leading services companies in different locations around the world. Dr. Gouty also has 15 years of prior industry experience with Eli Lilly, J&J, and smaller biotech companies.

Dr. Gouty is a leading expert in novel therapeutic biologics, gene therapy, cell therapy, and biosimilars. She has written several Books and authored over 150 scientific papers covering areas of new drug development/healthcare, and she holds patents on drugs and technologies which have contributed to bringing multiple drugs to market.  Dr. Gouty has a deep and expert knowledge on the evolving regulations of the FDA, EMA, and other regulatory agencies.

Want to Join Our Team?

Learn more about our culture and what makes Chimeron Bio an exciting place to work, and explore our current career opportunities.

Get Started